Plasminogen activator inhibitor-1: a risk factor for deep vein thrombosis after total hip arthroplasty

• Published in: Journal of orthopaedic surgery and research 2018-01, Vol.13 (1), p.8-8, Article 8
• Main Authors: Tang, Ju, Zhu, Wei, Mei, Xiaoliang, Zhang, Zhenxiang
• Format: Article
• Language: English
• Subjects: Comparative analysis; Complications and side effects; Deep vein thrombosis; Development and progression; Dosage and administration; Fibrinolytic agents; Health aspects; Hip replacement arthroplasty; Patient outcomes; Plasminogen activator inhibitor-1; Risk factor; Risk factors; Total hip arthroplasty; Venous thrombosis
• ISSN: 1749-799X; 1749-799X
• DOI: 10.1186/s13018-018-0716-2

The onset of deep vein thrombosis (DVT) in patients after total hip arthroplasty (THA) may expand or enlarge and subsequently lead to significant mortality. The objective of this study was to investigate potential risk factors for DVT in patients after THA. Eligible patients with hip joint diseases who were scheduled for unilateral primary THA at our hospital were prospectively included into this study. The demographic and clinical features, preoperative plasma biomarkers were detailed, recorded, and compared. The multiple logistic regression analysis was used to evaluate potential risk factors for DVT. A total of 214 subjects were enrolled into our study cohort for the final analysis, and 23 of them have suffered DVT with an incidence of 9.5%. The performance of logistic regression analysis showed that preoperative expression of plasminogen activator inhibitor-1 (PAI-1) was an independent risk factor for the onset of DVT in patients after THA (OR 1.18, 95% CI 1.04-1.29; p = 0.011). Our study indicated preoperative plasma PAI-1 expression as an independent risk factor for DVT in patients who underwent THA.